The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer Cell Lines is a research paper published in Cancers (2024). On theSindex it has a DataRank of 0.360. It has been cited 10 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institute of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)
Grant: R01NS110838
National Institute of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)
Grant: R01NS129744
National Institute of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)
Grant: 3000671
National Institutes of Health
Grant: 5R01NS129744-02
Quinolinate-induced immune suppression in glioblastoma
National Institutes of Health
Grant: 5R01NS110838-04
Developing therapeutic strategies to elicit metabolic synthetic lethality in glioblastoma
FWCI
2.66
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals